Issue 109 Item 3 AVANDIA MAY SLOW TYPE 2 PROGRESSION

(Watch for Actos to make same claim to fame) It only makes sense that all the insulin sensitizers will slow the progression of type 2 diabetes.
If you make the cells more sensitive to the bodies own insulin, it doesn’t have to produce as much and you won’t overwork the pancreas as much, therefore helping to prevent beta cell depletion.

Avandia(r) (rosiglitazone maleate) may improve beta cell function in the pancreas, according to data presented at the American Diabetes Association (ADA) 60th Scientific Sessions meeting.

Improving beta cell function may enhance long-term blood sugar control in type 2 diabetes patients, thereby slowing the progression of type 2 diabetes. Leading diabetes experts say that if this data is supported in long-term studies, improved beta cell function could have profound implications for preventing the complications of type 2 diabetes.

The United States Department of Veterans Affairs Health Administration (VA) is conducting a long-term nationwide study to determine the impact of intensive drug therapy with Avandia in combination with other type 2 diabetes drugs on preventing the life-threatening, long-term complications of type 2 diabetes. SmithKline Beecham is announcing at the ADA meeting that Avandia will be a key antidiabetes treatment investigated in this study.